Clinical Trial Update: Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment. [Phase 2]

View source ↗

Summary

Phase II trial evaluating peptide T in HIV-positive individuals with cognitive impairment has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hiv-associated Neurocognitive Disorder

Drugs mentioned

• Peptide T (peptide T)

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: HIV Infections, Cognition Disorders | Phase 2 | Status: COMPLETED | Results posted: 2015-08-04